Achieve Life Sciences, Inc. Payments for (Proceeds from) Short-term Investments
Achieve Life Sciences, Inc. (ACHV) reported Payments for (Proceeds from) Short-term Investments of $4.00 thousand for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-07-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromShortTermInvestments · last filed 2017-07-31
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for the quarter ending 2017-06-30 was -$1.00K, a 100.02% decline year-over-year.
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for the quarter ending 2017-03-31 was $5.00K, a 99.98% decline year-over-year.
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for the quarter ending 2016-12-31 was $2.38M, a 66.83% increase year-over-year.
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for the quarter ending 2016-09-30 was $5.01M, a 76.03% decline year-over-year.
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for fiscal 2016 was $36.50M, a 49.80% increase from fiscal 2015.
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for fiscal 2015 was $24.37M, a 25.31% increase from fiscal 2014.
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for fiscal 2014 was $19.45M, a 38.65% decline from fiscal 2013.
- Achieve Life Sciences, Inc. payments for (proceeds from) short-term investments for fiscal 2013 was $31.70M.
| Period end | Payments for (Proceeds from) Short-term Investments 3 month | Payments for (Proceeds from) Short-term Investments 6 month | Payments for (Proceeds from) Short-term Investments 9 month | Payments for (Proceeds from) Short-term Investments 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-31 | $4.00K 10-Q · filed 2017-07-31 | $2.38M derived: sum of 3 quarters · filed 2017-07-31 | $7.40M derived: sum of 4 quarters · filed 2017-07-31 |
| 2017-03-31 | $5.00K 10-Q · filed 2017-05-15 | $2.38M derived: sum of 2 quarters · filed 2017-05-15 | $7.40M derived: sum of 3 quarters · filed 2017-05-15 | $12.34M derived: sum of 4 quarters · filed 2017-07-31 |
| 2016-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $7.39M derived: sum of 2 quarters · filed 2017-02-23 | $12.34M derived: sum of 3 quarters · filed 2017-07-31 | $36.50M 10-K · filed 2017-02-23 |
| 2016-09-30 | $5.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $9.96M derived: sum of 2 quarters · filed 2017-07-31 | $34.13M 10-Q · filed 2016-11-10 | $35.55M derived: sum of 4 quarters · filed 2017-07-31 |
| 2016-06-30 | $4.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-31 | $29.11M 10-Q · filed 2017-07-31 | $30.54M derived: sum of 3 quarters · filed 2017-07-31 | $51.45M derived: sum of 4 quarters · filed 2017-07-31 |
| 2016-03-31 | $24.17M 10-Q · filed 2017-05-15 | $25.59M derived: sum of 2 quarters · filed 2017-05-15 | $46.51M derived: sum of 3 quarters · filed 2017-05-15 | $49.61M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $22.34M derived: sum of 2 quarters · filed 2017-02-23 | $25.44M derived: sum of 3 quarters · filed 2017-02-23 | $24.37M 10-K · filed 2017-02-23 |
| 2015-09-30 | $20.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $24.01M derived: sum of 2 quarters · filed 2016-11-10 | $22.94M 10-Q · filed 2016-11-10 | $37.11M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $2.02M 10-Q · filed 2016-08-04 | $16.19M derived: sum of 3 quarters · filed 2017-02-23 | $21.26M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | -$1.07M 10-Q · filed 2016-05-12 | $13.10M derived: sum of 2 quarters · filed 2017-02-23 | $18.16M derived: sum of 3 quarters · filed 2017-02-23 | $18.32M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $14.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $19.23M derived: sum of 2 quarters · filed 2017-02-23 | $19.39M derived: sum of 3 quarters · filed 2017-02-23 | $19.45M 10-K · filed 2017-02-23 |
| 2014-09-30 | $5.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $5.23M derived: sum of 2 quarters · filed 2015-11-12 | $5.28M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $215.00K 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $51.00K 10-Q · filed 2015-05-14 | |||
| 2013-12-31 | $31.70M 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |